Screener Summaries Updates Institutions Sign In More Updates › Other Events › ENTA Other Events · Jun 23, 2026
The Federal Circuit affirmed a summary judgment decision ruling that the claims of U.S. Patent No. 11,358,953 are… ENTA Enanta Pharmaceuticals Inc
The Federal Circuit affirmed a summary judgment decision ruling that the claims of U.S. Patent No. 11,358,953 are invalid, impacting Enanta Pharmaceuticals' lawsuit against Pfizer Inc. regarding Paxlovid infringement. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs.
More from Enanta Pharmaceuticals Inc UPC rules Enanta's patent invalid in Pfizer Paxlovid infringement case Oct 29, 2026 Enanta CEO Jay Luly to retire Feb 1; appoints Tara Kieffer COO Oct 28, 2026 Enanta Pharmaceuticals reported fiscal third quarter results ending June 30, 2026 Aug 10, 2026 Enanta Pharmaceuticals, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $75,000,000… Jul 2, 2026 Enanta Pharmaceuticals, Inc. announced the advancement of its zelicapavir clinical development program for the… Jun 18, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
